Alloy Therapeutics Inc.

09/04/2023 | Press release | Archived content

High Efficiency CAR Discovery Screening

Chimeric antigen receptor cell therapy (CAR-T, CAR-NK, etc.) is a promising therapeutic modality, but functional screening is a bottleneck for traditional two-step CAR-T discovery process of antibody binder discovery and CAR-T functional engineering. In this webinar, scientists at Alloy showcase their unique CAR discovery workflow that incorporates human antibody identification and characterization, mRNA-based CAR construct generation, and in vitro and in vivo functional screening. Learn from the discovery scientists that helm this process and help cell therapy companies and discovery teams identify functional chimeric antigen receptors three months faster than conventional approaches.

High Efficiency CAR T Discovery & Screening

Alloy Therapeutics Inc. published this content on September 04, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on February 20, 2026 at 12:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]